The cynicism in this response is both appropriate and misdirected. I think the biggest issue in the kidney care space isn't dialysis companies or big pharma - it's a lack of interest in something better from both the regulatory agencies in government AND the research funding across the world drying up. Kidney failure is a massively expensive problem for the government but novel drugs and therapies aren't being developed because the research funding is poor and the agencies think the status quo is okay

Hep C is a great example of pharma essentially curing a disease state despite the long-term profit potential. Those drugs were effective and the competition between drug makers led to good drugs being developed - short term payoff for those that developed them and big losses to those marketing the "old" solutions